💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Carbidopa

CHEMBL1200748 Phase 4 अनुमोदित Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
226.2 g/mol
LogP
-2.2
Phase
4

This drug works by blocking the conversion of levodopa into dopamine outside the brain, ensuring more levodopa reaches the central nervous system where it is needed. It is used in combination with levodopa to treat Parkinson's disease and related movement disorders. By reducing peripheral dopamine production, it also lessens side effects such as nausea and vomiting.

आणविक भार

226.2300 g/mol

LogP

-2.20

TPSA

116.00 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

अस्थमा उच्च रक्तचाप एज-रिलेटेड मैक्युलर डिजनरेशन टाइप 2 मधुमेह दर्द प्रबंधन दीर्घकालिक दर्द पार्किंसन रोग मल्टीपल स्क्लेरोसिस मेजर डिप्रेसिव डिसऑर्डर सिज़ोफ्रेनिया स्ट्रोक

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O.O

                

                

                
                

                    
InChI

                    
InChI=1S/C10H14N2O4.H2O/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H2/t10-;/m0./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C10H14N2O4

                    

                    
                    

                        
HBD / HBA

                        
5 / 6

                    

                    
                    

                        
घूर्णनीय बंधन

                        
4

                    

                    
                    
                    

                        
भारी परमाणु

                        
16

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
This drug works by blocking the conversion of levodopa into dopamine outside the brain, ensuring more levodopa reaches the central nervous system where it is needed. It is used in combination with levodopa to treat Parkinson's disease and related movement disorders. By reducing peripheral dopamine production, it also lessens side effects such as nausea and vomiting.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Carbidopa is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1200748.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 34359.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.